Lung cancer response to gefitinib, then erlotinib, then gefitinib again

Lung cancer response to gefitinib, then erlotinib, then gefitinib again

10.1097/JTO.0b013e318183afb0

Saved in:

Bibliographic Details
Main Authors:	Wong, A.S., Seto, K.-Y., Chin, T.-M., Soo, R.A.
Other Authors:	NATIONAL UNIVERSITY MEDICAL INSTITUTES
Format:	Others
Published:	2014
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/109795
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
by: Afrita Amalia Laitupa, -, et al.
Published: (2019)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Lee C., et al.
Published: (2017)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer
by: Zee, Y.-K., et al.
Published: (2014)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
by: Wang, L.-Z., et al.
Published: (2014)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
by: Auliya Hafizah, Raysa

SYNTHESIS OF VARIOUS GEFITINIB INTERMEDIATE DERIVATIVE AS ANTI-CANCER DRUGS
by: Lutfi Sa'adah, Pipih

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
by: Sudo M., et al.
Published: (2020)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year
by: Charoentum C.
Published: (2014)

Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year
by: Chaiyut Charoentum
Published: (2018)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
by: James Chih Hsin Yang, et al.
Published: (2018)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by: De Lima Lopes Jr., G., et al.
Published: (2016)

PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS DR SOETOMO SURABAYA
by: Afrita Amalia Laitupa
Published: (2019)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert S., et al.
Published: (2014)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
by: Cho B.C.
Published: (2023)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
by: Mark Boye, et al.
Published: (2018)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
by: Chaichana Chantharakhit
Published: (2019)

Erlotinib in previously treated non-small-cell lung cancer
by: Frances A. Shepherd, et al.
Published: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Wu Y.-L., et al.
Published: (2014)

An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer [2]
by: Toh, C.-K., et al.
Published: (2014)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
by: Scagliotti G.V., et al.
Published: (2014)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
by: Giorgio V. Scagliotti, et al.
Published: (2018)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK DENGAN EGFR MUTASI EXON 19 DAN EXON 21
by: Titin Sholihah Agustina, NIM011180901
Published: (2017)

Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated the metabolism of gefitinib, lapatinib and sorafenib
by: Rodseeda C.
Published: (2023)

Khảo sát tình hình sử dụng Gefitinib trong bệnh ung thư phổi không tế bào nhỏ
by: Phạm, Thị Khánh Chi
Published: (2020)

How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma?
by: Wong, A.S., et al.
Published: (2014)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017)